Controlling parasitic infestations in livestock and domestic animals presents a significant challenge for modern agriculture and veterinary care. When addressing the complexities of China/Custom myiasis or nasal myiasis, precision in pharmaceutical formulation is non-negotiable. Shijiazhuang Huajun Animal Pharmaceutical Co., Ltd. (ZTHJ Pharma) addresses these challenges through a high-tech R&D approach, leveraging over 15 years of industry expertise since our establishment in 2008.
Our 21,000-square-meter facility in Xinle City is designed to provide high-efficacy treatments that stop larvae development and protect animal respiratory health. By integrating specific antigens and advanced peptides into our pharmaceutical solutions, we ensure that our treatments for myiasis offer more than just surface-level relief—they provide systemic protection and long-term prevention.
The efficacy of any treatment for China/Custom myiasis or nasal myiasis is rooted in the rigor of its production standards. In 2022, ZTHJ Pharma successfully passed the new veterinary drug GMP acceptance by the Ministry of Agriculture, ensuring that every powder, oral solution, and premix we produce meets the highest global safety benchmarks.
| Performance Metric | Industry Significance | Our Engineering Standard | Advantage |
|---|---|---|---|
| Active Ingredient Purity | Determines larval mortality rates. | Pharmaceutical-grade Ivermectin & Antigens | Rapid elimination of nasal larvae. |
| Facility Certification | Ensures batch-to-batch consistency. | 2022 Ministry of Agriculture GMP | Global export compliance & safety. |
| Formulation Versatility | Allows for multiple delivery methods. | Oral, Powder, and Liquid Lines | Easy administration across 100+ varieties. |
| Bioavailability | Speed of therapeutic action. | Advanced Peptide Integration | Faster recovery for infected livestock. |
By focusing on specific pharmaceutical guides, such as our recent 2026 analysis of antiparasitic applications, we provide our global partners with the technical documentation needed to manage custom infestation cases effectively.
Investing in high-quality veterinary interventions is a strategic financial decision. Untreated China/Custom myiasis or nasal myiasis leads to significant loss in animal weight, decreased milk production, and high mortality rates in poultry and livestock. Our multi-language support—spanning Arabic, French, German, and Spanish—reflects our commitment to helping international markets achieve better animal health outcomes and higher returns on investment.
With a production capacity covering 100+ varieties of medicines, ZTHJ Pharma empowers distributors and farm managers to reduce the "cost of neglect." Our Bacillus Coagulans SNZ 1969 and probiotic-enhanced formulations further support the immune system of treated animals, ensuring they return to peak productivity faster than with generic alternatives.
Related products
Top Selling Products
